AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02609321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
Study NCT02609321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Wound Infiltration
Description: Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
Study NCT00411177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post-dilution on-line hemodiafiltration
Description: post-dilution on-line hemodiafiltration, 3 times a week 4 hours
Study NCT00411177 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high flux hemodialysis
Description: High-flux hemodialysis, 3 times a week 4 hours
Study NCT01725269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001
Description: All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Study NCT03646526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）
Description: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
Study NCT01887418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QuickShot™ - 50 mg Treatment B
Description: QuickShot™ for the delivery of testosterone
Study NCT01887418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QuickShot™ - 100 mg Treatment A
Description: QuickShot™ for the delivery of testosterone
Study NCT03646526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）
Description: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
Study NCT01887418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delatestryl 200 mg IM Treatment C
Description: Standard of care
Study NCT02238691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mask ventilation with PEEP via a face mask device
Description: 15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask.
Study NCT04787718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: 2.0 oz of raw, shelled, unsalted almonds
Study NCT04787718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: an isocaloric amount of unsalted pretzels
Study NCT03628456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest
Study NCT03628456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill-Rom Monarch
Description: High-frequency chest wall oscillation vest
Study NCT03696602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial provocation test
Study NCT00084747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT02728375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer game based rehabilitation protocol
Description: Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
Study NCT02728375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy protocol
Description: In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
Study NCT02535962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus and Bifidobacterium lactis
Description: study product will be freeze dried and put into foil sachets
Study NCT02535962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
Study NCT04091412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
Study NCT04561557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT103A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.
Study NCT03410108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablet
Study NCT00853021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
Study NCT00853021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
Study NCT00877188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: supervised combined aerobic and progressive resistance training for 12 weeks
Study NCT04561557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.
Study NCT04563884 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart.
Study NCT03454165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BNC105P
Description: BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
Study NCT03454165 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: A novel BTK inhibitor.
Study NCT03857568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: drug will be dosed repeatedly
Study NCT03857568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be dosed repeatedly
Study NCT03633929 — intervention group
Intervention type: OTHER
Intervention: KIOS OUD
Description: Study Participants will evaluate software known as KIOS-OUD
Study NCT03404102 — intervention group
Intervention type: DEVICE
Intervention: Cu-IUD
Description: Copper Intra-uterine device used as contraceptive method
Study NCT01495884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-pegylated liposomal doxorubicon (Myocet™)
Study NCT01495884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (Tyverb™)
Study NCT04119453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablets
Study NCT00738686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary stent implantation
Description: Taxus stent implantation in patients with multivessel coronary artery disease
Study NCT04566003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.
Study NCT04566003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
Study NCT04566003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-6240
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
Study NCT01961154 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Asthma medication reduction
Description: The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
Study NCT01949844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
Study NCT01949844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Optimark®
Description: For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
Study NCT01949844 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Myocardial perfusion MRI
Study NCT03651427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Induced hypogonadism and re-institution of CSHT
Study NCT00756236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: 60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
Study NCT00756236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: 60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
Study NCT00756236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-Group
Description: 0.9%NaCl dispensed in 60ml \& 5ml syringes
Study NCT00186979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.
Description: See Detailed Description section for details of treatment interventions.
Study NCT01105702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT01105702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01105702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study NCT01077037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Chest pain choice decision aid
Study NCT01105702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01951612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Function Training Program
Description: Participants will take part in ten 2-hour sessions over 5 weeks.
Study NCT01951612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Training Program
Description: Participants will take part in ten 2-hour sessions over 5 weeks.
Study NCT02355821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Study NCT02355821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Study NCT00585845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
Description: 2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.
Study NCT00643825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
Study NCT00643825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Observation till Progression then rechallenging with TMZ
Study NCT04427475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pabolizumab
Description: 100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
Study NCT04427475 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nafulizumab
Description: nafulizumab
Study NCT03826264 — intervention group
Intervention type: PROCEDURE
Intervention: TAVR
Description: transcatheter aortic valve replacement (TAVR)
Study NCT03512717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenfill
Description: Maximum: 22ml
Study NCT03512717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerfill
Description: Maximum: 22ml
Study NCT06048562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: evaluation idm for cardiomyopathy by echo
Study NCT03069261 — intervention group
Intervention type: DEVICE
Intervention: Indocyanine green angiography
Study NCT03513809 — intervention group
Intervention type: DEVICE
Intervention: Thoracic electrical impedance tomography
Description: Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
Study NCT04308902 — intervention group
Intervention type: OTHER
Intervention: VLBW
Description: Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
Study NCT02200536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant oral health promotion package
Description: Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
Study NCT02200536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant oral health pamphlet
Description: Infant oral health pamphlet
Study NCT02591901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uro vaxom
Description: Prevention of recurrent symptomatic lower urinary tract infections
Study NCT02591901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study NCT05130710 — intervention group
Intervention type: PROCEDURE
Intervention: staging laparoscopy
Description: All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
Study NCT01931956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip® implant
Description: Percutaneous mitral valve repair using MitraClip implant
Study NCT01757938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shang Ring Guided Circumcision
Study NCT01757938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps Guided Circumcision
Study NCT02310425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S. boulardii
Description: 50 mg/kg twice daily
Study NCT02310425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: he control group (group C) did not receive S. boulardii (nor other probiotics)
Study NCT01088178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Description: Placement of Mirena at given intervals during the postpartum period
Study NCT04308902 — intervention group
Intervention type: OTHER
Intervention: Term-born Comparison
Description: Children born >=37 weeks gestation and weighing more than 2500g
Study NCT01999543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based dietary supplement
Study NCT01999543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: plant-based dietary supplement
Study NCT01999543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01999543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT02109861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
Study NCT02109861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
Study NCT02109861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
Study NCT01046058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
Study NCT00185640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
Study NCT00185640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
Study NCT00185640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
Study NCT00185640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: * Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day
Study NCT00185640 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: 0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
Study NCT04256356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder
Description: Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.